| Serial Number | 87677145 |
| Word Mark | BECAFRI |
| Filing Date | Wednesday, November 8, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, February 14, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 13, 2018 |
| Goods and Services | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, November 19, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Allergan Pharmaceuticals International Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Coolock, Dublin 17 IE |
| Party Name | Allergan Pharmaceuticals International Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Coolock, Dublin 17 IE |
| Event Date | Event Description |
| Monday, February 14, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, February 14, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, July 14, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, July 13, 2021 | SOU EXTENSION 5 GRANTED |
| Tuesday, July 6, 2021 | SOU EXTENSION 5 FILED |
| Tuesday, July 13, 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, July 6, 2021 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, January 6, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, January 4, 2021 | SOU EXTENSION 4 GRANTED |
| Monday, January 4, 2021 | SOU EXTENSION 4 FILED |
| Monday, January 4, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, June 16, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, June 12, 2020 | SOU EXTENSION 3 GRANTED |
| Friday, June 12, 2020 | SOU EXTENSION 3 FILED |
| Friday, June 12, 2020 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, December 24, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, December 20, 2019 | SOU EXTENSION 2 GRANTED |
| Friday, December 20, 2019 | SOU EXTENSION 2 FILED |
| Friday, December 20, 2019 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, June 11, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, June 7, 2019 | SOU EXTENSION 1 GRANTED |
| Friday, June 7, 2019 | SOU EXTENSION 1 FILED |
| Friday, June 7, 2019 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, January 8, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 13, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 13, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 24, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Friday, October 5, 2018 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Tuesday, October 2, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, August 31, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, August 31, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 29, 2018 | ASSIGNED TO LIE |
| Monday, August 13, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, February 27, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, February 27, 2018 | NON-FINAL ACTION E-MAILED |
| Tuesday, February 27, 2018 | NON-FINAL ACTION WRITTEN |
| Tuesday, February 20, 2018 | ASSIGNED TO EXAMINER |
| Sunday, November 19, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, November 11, 2017 | NEW APPLICATION ENTERED |